The current study was designed to evaluate the efficacy of the investigational Plk1 inhibitor TAK-960 in colorectal cancer (CRC) models as a single agent and to determine the anti-cancer effects of TAK-960 in combination with standard agents in patient-derived CRC xenografts. This evidence concerns the gene PLK1 and cancer.